The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab combined with concurrent chemoradiotheray in Chinese patients with unresectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trial.
Xue Meng
No relevant relationships to disclose
Jianhua Wang
No relevant relationships to disclose
Xindong Sun
No relevant relationships to disclose
Lvhua Wang
No relevant relationships to disclose
Ming Ye
No relevant relationships to disclose
Ping bo Feng
No relevant relationships to disclose
Guangying Zhu
No relevant relationships to disclose
You Lu
No relevant relationships to disclose
Chun Han
No relevant relationships to disclose
Shu chai Zhu
No relevant relationships to disclose
Zhongxing X. Liao
No relevant relationships to disclose
Jinming Yu
No relevant relationships to disclose